While subsequent work suggests that colorectal cancer cells may express cancer-associated OATP1B3 variants with reduced transport activity [60], this does not exclude residual functional uptake, inter tumour heterogeneity, contribution from additional uptake systems, or culture dependent regulation of transporter expression that together can permit sufficient intracellular exposure for pharmacological activity. This evidence concerns the gene SLCO1B3 and colorectal cancer.